Does pharmacokinetic variability influence the efficacy of high-dose methotrexate for the treatment of children with acute lymphoblastic leukemia: what can we learn from small studies?

Leuk Res. 1997 May;21(5):435-7. doi: 10.1016/s0145-2126(96)00128-2.
No abstract available

Publication types

  • Comment
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Child
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Humans
  • Methotrexate / pharmacokinetics*
  • Methotrexate / therapeutic use
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Prognosis
  • Recurrence
  • Risk Assessment

Substances

  • Antimetabolites, Antineoplastic
  • Methotrexate